Special Issue "Emerging Pain Targets and Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2012)
Dr. Kim Lawson
Department of Biosciences, Biomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, City Campus, Sheffield, S1 1WB, UK
Interests: fibromyalgia; pain; potassium channels; drug design/discovery
Pain remains a major clinical challenge with the management of pain the most frequent issue encountered by clinicians. Many current analgesics are limited by serious unwanted effects, while for some pain conditions there are no effective analgesics. Advances in molecular biological techniques that have enabled the discovery of specific molecules involved in pain production have contributed to a better understanding of pain and the mechanisms of different types of pain and are providing clues for the development of novel pharmacotherapies for specific pain types. This increased understanding of pain physiology has offered a number of potential targets (e.g. TRPV1, voltage-gated sodium channels, calcium channels, glutamate receptors, cannabinoids) for future treatments, in particular for neuropathic and chronic pain. This special issue is intended to provide the reader with an insight into the progress made in this field through novel contributions of original papers and critical reviews.
Dr. Kim Lawson
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- pain pathways
- emerging targets
- molecular biology
- novel therapies
- ion channels
Article: Real-Time Translocation and Function of PKCβII Isoform in Response to Nociceptive Signaling via the TRPV1 Pain Receptor
Pharmaceuticals 2011, 4(11), 1503-1517; doi:10.3390/ph4111503
Received: 12 October 2011; in revised form: 26 October 2011 / Accepted: 7 November 2011 / Published: 11 November 2011| Download PDF Full-text (1086 KB) | Download XML Full-text | Supplementary Files
Review: New Strategies to Develop Novel Pain Therapies: Addressing Thermoreceptors from Different Points of View
Pharmaceuticals 2012, 5(1), 16-48; doi:10.3390/ph5010016
Received: 16 November 2011; in revised form: 16 December 2011 / Accepted: 21 December 2011 / Published: 27 December 2011| Download PDF Full-text (1565 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(2), 114-132; doi:10.3390/ph5020114
Received: 18 November 2011; in revised form: 18 January 2012 / Accepted: 26 January 2012 / Published: 2 February 2012| Download PDF Full-text (473 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(3), 249-278; doi:10.3390/ph5030249
Received: 4 January 2012; in revised form: 4 February 2012 / Accepted: 15 February 2012 / Published: 23 February 2012| Download PDF Full-text (287 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(8), 837-852; doi:10.3390/ph5080837
Received: 29 June 2012; in revised form: 2 August 2012 / Accepted: 15 August 2012 / Published: 17 August 2012| Download PDF Full-text (140 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(10), 1045-1053; doi:10.3390/ph5101045
Received: 2 July 2012; in revised form: 6 September 2012 / Accepted: 17 September 2012 / Published: 27 September 2012| Download PDF Full-text (209 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of the Paper: Review
Title: Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases
Authors: Fumio Tsuji and Hiroyuki Aono
Affiliation: Research and Development Center, Santen Pharmaceutical Co.,Ltd., Japan; E-Mail: firstname.lastname@example.org
Abstract: The transient receptor potential vanilloid-1 (TRPV1) cationchannel is a receptor that is activated by noxious temperatures, as well as to chemical agonists, such as vanilloids and protons. With these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. As many proalgesic pathways converge on TRPV1 and it is upregulated and sensitized by inflammation and injury, TRPV1 is thought to be a central transducer of hyperalgesia and a prime target for the pharmacological control of pain. However, there is conflicting evidence to date as to whether TRPV1 agonists promote or inhibit inflammation. We recently demonstrated that SA13353 [1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea], a novel TRPV1 agonist, inhibits tumor necrosis factor-? production through the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms of kidney injury, lung inflammation, arthritis and encephalomyelitis in disease models. These results suggest that TRPV1 agonists may act in an anti-inflammatory manner in vivo in certain inflammatory and autoimmune diseases and conditions. The use of potent TRPV1 antagonists as a general strategy to treat inflammation must be cautiously considered, given the deleterious effects that may arise from inhibiting the population of channels that have a protective function. Further studies to clarify the role of TRPV1 in inflammation and autoimmune diseases are therefore necessary.
Last update: 18 May 2012